We are live on
!
Find out more
AAP
Arax Advisory Partners Portfolio holdings
AUM
$3.54B
1-Year Est. Return
19.14%
This Fund
S&P 500
This Quarter
Est. Return
+8.04%
1 Year Est. Return
+19.14%
3 Year Est. Return
+47.9%
5 Year Est. Return
+48.74%
10 Year Est. Return
–
AUM
$2.18B
AUM Growth
+$617M
(+40%)
Cap. Flow
+$399M
Cap. Flow
% of AUM
18.35%
Top 10 Holdings %
Top 10 Hldgs %
22.83%
Holding
3,224
New
565
Increased
1,310
Reduced
679
Closed
193
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AXON
Axon Enterprise
AXON
|
+$52.4M |
| 2 |
Panagram BBB-B CLO ETF
CLOZ
|
+$37.6M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$29.3M |
| 4 |
Janus Henderson AAA CLO ETF
JAAA
|
+$24.4M |
| 5 |
Merck
MRK
|
+$21.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
+$21.9M |
| 2 |
iShares Russell Mid-Cap Growth ETF
IWP
|
+$20.7M |
| 3 |
iShares S&P 500 Value ETF
IVE
|
+$19.4M |
| 4 |
iShares Ultra Short Duration Bond Active ETF
ICSH
|
+$19.2M |
| 5 |
Invesco Ultra Short Duration ETF
GSY
|
+$19.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 6.5% |
| 2 | Financials | 4.24% |
| 3 | Healthcare | 3.21% |
| 4 | Consumer Discretionary | 2.76% |
| 5 | Industrials | 2.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2551
GXO Logistics
GXO
$5.48B
| $2.14K | ﹤0.01% |
44
-46
| -51% | -$1.83K |
|
2552
Supernus Pharmaceuticals
SUPN
$2.73B
| $2.14K | ﹤0.01% |
68
+26
| +62% | +$833 |
|
2553
Flywire
FLYW
$2.3B
| $2.14K | ﹤0.01% |
63
-74
| -54% | -$754 |
|
2554
Arvinas
ARVN
$542M
| $2.13K | ﹤0.01% |
+289
| New | +$2.13K |
|
2555
X4 Pharmaceuticals
XFOR
$391M
| $2.13K | ﹤0.01% |
+1,120
| New | +$4.58K |
|
2556
Dine Brands
DIN
$453M
| $2.12K | ﹤0.01% |
87
+26
| +43% | +$601 |
|
2557
Humacyte
HUMA
$197M
| $2.09K | ﹤0.01% |
1,000
| – | – |
|
2558
Myers Industries
MYE
$1.33B
| $2.09K | ﹤0.01% |
144
-29
| -17% | -$353 |
|
2559
Boise Cascade
BCC
$2.96B
| $2.08K | ﹤0.01% |
24
-50
| -68% | -$4.53K |
|
2560
ProFrac Holding
ACDC
$814M
| $2.07K | ﹤0.01% |
267
+81
| +44% | +$530 |
|
2561
Franklin Electric
FELE
$4.87B
| $2.06K | ﹤0.01% |
23
+6
| +35% | +$526 |
|
2562
Ubiquiti
UI
$34.4B
| $2.06K | ﹤0.01% |
5
-2
| -29% | -$728 |
|
2563
West Bancorporation
WTBA
$482M
| $2.02K | ﹤0.01% |
103
+49
| +91% | +$947 |
|
2564
Helios Technologies
HLIO
$2.72B
| $2K | ﹤0.01% |
+60
| New | +$1.81K |
|
2565
Ultragenyx Pharmaceutical
RARE
$2.46B
| $2K | ﹤0.01% |
55
-23
| -29% | -$829 |
|
2566
Hovnanian Enterprises
HOV
$808M
| $1.99K | ﹤0.01% |
+19
| New | +$1.86K |
|
2567
Vir Biotechnology
VIR
$1.54B
| $1.99K | ﹤0.01% |
394
+276
| +234% | +$1.48K |
|
2568
La-Z-Boy
LZB
$1.66B
| $1.97K | ﹤0.01% |
53
+35
| +194% | +$1.4K |
|
2569
Alamo Group
ALG
$2.04B
| $1.97K | ﹤0.01% |
9
-11
| -55% | -$2.1K |
|
2570
Fortuna Silver Mines
FSM
$2.91B
| $1.96K | ﹤0.01% |
300
| – | – |
|
2571
Madison Square Garden
MSGE
$3.68B
| $1.96K | ﹤0.01% |
49
| – | – |
|
2572
PTC Therapeutics
PTCT
$5.78B
| $1.95K | ﹤0.01% |
+40
| New | +$1.9K |
|
2573
Liberty Live Group Series C
LLYVK
$9.54B
| $1.95K | ﹤0.01% |
24
+5
| +26% | +$369 |
|
2574
Fidelity MSCI Real Estate Index ETF
FREL
$1.5B
| $1.95K | ﹤0.01% |
+72
| New | +$1.92K |
|
2575
Syndax Pharmaceuticals
SNDX
$1.78B
| $1.94K | ﹤0.01% |
+207
| New | +$2.28K |
|
Similar funds
TYCC
TH
BCP
WWA
VPC
BPS
TCM
DILIC
Arax Advisory Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Arax Advisory Partners held 3,224 positions worth $2.18B, up 40% from $1.56B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Arax Advisory Partners deployed $399M of net new capital in Q2 2025, opening 565 new positions and adding to 1,310 existing holdings. Its largest new stake was Panagram BBB-B CLO ETF: 1,423,147 shares worth $38.1M.
By sector, the portfolio is most concentrated in Technology at 6.5% of assets, up from 5.4% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was State Street SPDR Bloomberg 1-3 Month T-Bill ETF, an estimated $21.9M trimmed.
- Arax Advisory Partners's largest Q2 2025 buy was Panagram BBB-B CLO ETF: 1,423,147 shares worth $38.1M.
- Arax Advisory Partners added most to Axon Enterprise in Q2 2025, an estimated $52.4M increase.
- Arax Advisory Partners's biggest Q2 2025 reduction was State Street SPDR Bloomberg 1-3 Month T-Bill ETF, cutting an estimated $21.9M.
- Arax Advisory Partners fully exited YieldMax MSTR Option Income Strategy ETF in Q2 2025, selling an estimated $102K.
- Arax Advisory Partners's ten largest holdings make up 23% of its $2.18B portfolio in Q2 2025.
- Arax Advisory Partners opened 565 new positions and closed 193 in Q2 2025.
- Arax Advisory Partners's portfolio value rose 40% quarter-over-quarter to $2.18B.
Based on Arax Advisory Partners's 13F filing for Q2 2025, filed 12 Aug 2025.